Gurminder Kaur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gurminder Kaur has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Praveen Chandra Verma
Academy of Scientific and Innovative Research (AcSIR)
4 shared publications - Deepak Ganjewala
531065 Amity Institute of Biotechnology, Amity University Uttar Pradesh , Sector-125 , Noida , 201303 , India
3 shared publications Sanchita Singh
3 shared publications- David W. Ow
Plant Gene Engineering Center, Chinese Academy of Sciences, Guangzhou 510650, China
2 shared publications Deepak Ganjewala
Amity University
2 shared publicationsGauri Saxena
University of Lucknow
2 shared publications
Latest Publications
- 24 November 2019
- Published by Springer Nature
- p. 197-216
Stress Protectant Secondary Metabolites and their Metabolic Engineering to Enhance Abiotic Stress Tolerance in Plants
- 24 November 2019
- Published by Springer Nature
- p. 197-216
Stress Protectant Secondary Metabolites and their Metabolic Engineering to Enhance Abiotic Stress Tolerance in Plants
- 2 October 2019
- Published by Springer Nature
- p. 487-499
Role of Endosymbionts in Nutritional Uptake of Sap Sucking Insects
- 2 October 2019
- Published by Springer Nature
- p. 487-499
Role of Endosymbionts in Nutritional Uptake of Sap Sucking Insects
- 2 October 2019
- Published by Springer Nature
- p. 249-263
An Update on the Applications of CRISPR/Cas9 Technology in Tomato
- 2 October 2019
- Published by Springer Nature
- p. 249-263
An Update on the Applications of CRISPR/Cas9 Technology in Tomato
- 2 October 2019
- Published by Springer Nature
- p. 207-227
Metabolic Engineering of Stress Protectant Secondary Metabolites to Confer Abiotic Stress Tolerance in Plants
- 2 October 2019
- Published by Springer Nature
- p. 207-227
Metabolic Engineering of Stress Protectant Secondary Metabolites to Confer Abiotic Stress Tolerance in Plants
- Open Access
- 25 May 2019
- Published by Wiley in Plant Biotechnology Journal
- Vol. 17 (11) , 2029-2031
Replacement of stacked transgenes in planta
- 25 May 2019
- Published by Wiley in Plant Biotechnology Journal
- Vol. 17 (11) , 2029-2031
Open AccessReplacement of stacked transgenes in planta
- 3 April 2019
- Published by Taylor & Francis in Archives of Phytopathology and Plant Protection
- Vol. 52 (5-6) , 458-469
Antifungal and larvicidal activities of two acyclic monoterpenes; citral and geraniol against phytopathogenic fungi and insects
Citral and geraniol are dominating constituents of lemon and rose scented essential oils of Cymbopogon spp. Here, we report their antifungal activity against some pathogenic fungi Drechslera oryzae, Fusarium oxysporum, Rhizoctonia solani and Sclerotium rolfsii and larvicidal activity against two insects Helicoverpa armigera and Spodoptera litura. Results revealed that both citral and geraniol exhibited strong fungicidal effects at concentrations > 0.2 µL mL−1. Citral was found most active against F. oxysporum and S. rolfsii while geraniol against S. rolfsii at 0.2–2 µL mL−1. Nanoemulsions of citral and geraniol caused 91 and 94% larval mortality of H. armigera and S. litura, respectively, at 1% concentration. Hence, the study revealed potential antifungal and larvicidal activities of citral and geraniol, which can be implicated in formulation of biocides for effective control of phytopathogenic fungal and insects.
- 3 April 2019
- Published by Taylor & Francis in Archives of Phytopathology and Plant Protection
- Vol. 52 (5-6) , 458-469
Antifungal and larvicidal activities of two acyclic monoterpenes; citral and geraniol against phytopathogenic fungi and insects
Citral and geraniol are dominating constituents of lemon and rose scented essential oils of Cymbopogon spp. Here, we report their antifungal activity against some pathogenic fungi Drechslera oryzae, Fusarium oxysporum, Rhizoctonia solani and Sclerotium rolfsii and larvicidal activity against two insects Helicoverpa armigera and Spodoptera litura. Results revealed that both citral and geraniol exhibited strong fungicidal effects at concentrations > 0.2 µL mL−1. Citral was found most active against F. oxysporum and S. rolfsii while geraniol against S. rolfsii at 0.2–2 µL mL−1. Nanoemulsions of citral and geraniol caused 91 and 94% larval mortality of H. armigera and S. litura, respectively, at 1% concentration. Hence, the study revealed potential antifungal and larvicidal activities of citral and geraniol, which can be implicated in formulation of biocides for effective control of phytopathogenic fungal and insects.
- 28 November 2018
- Published by Springer Nature
- p. 295-310
An Update on Transcriptome Sequencing of Hairy Root Cultures of Medicinally Important Plants
- 28 November 2018
- Published by Springer Nature
- p. 295-310
An Update on Transcriptome Sequencing of Hairy Root Cultures of Medicinally Important Plants
- 16 October 2017
- Published by Springer Nature in Current Molecular Biology Reports
- Vol. 3 (4) , 306-316
Recombinant Plant Engineering for Immunotherapeutic Production
Purpose of Review The requirement for large quantities of therapeutic proteins has fueled a great interest in the production of recombinant proteins in plant bioreactors. The vaccines and bio-therapeutic protein production in plants hold the promise of significantly lowering the cost of manufacturing life-saving drugs. This review will reflect the current status and challenges that the molecular farming platform faces becoming a strategic solution for the development of low-cost bio-therapeutics for developing countries. Recent Findings Different plant parts have been successfully identified as suitable expression systems for the commercial production of therapeutic proteins for some human and animal diseases ranging from common cold to AIDS. The processed therapeutics from such sources are devoid of any toxic components. The large-scale cultivation of these transgenic plants would be possible anywhere in the world including developing countries, which lack sophisticated drug manufacturing units. A couple of such commercially generated products have already hit the market with success. Newer methods using suitable plant viruses and recombinant gene expression systems have already been devised for producing therapeutic proteins and peptides. Summary Plants are promising bio-factories for therapeutic protein production because of their several advantages over the other expression systems especially the advanced mechanisms for protein synthesis and post-translational modification which are very much similar to animal cells. Plant biotechnologists are much attracted to the bio-farming because of its flexibility, scalability, low manufacturing cost, as well as the lack of risk of toxic or pathogenic contamination. A number of projects on bio-farming are designed and are at various developmental stages but have not yet become available to the pharmaceutical industry. Therefore, we need further advancement in the optimization of lab protocols for up-scaling the production of such therapeutics at commercial level with a promise to offer their best clinical use.
- 16 October 2017
- Published by Springer Nature in Current Molecular Biology Reports
- Vol. 3 (4) , 306-316
Recombinant Plant Engineering for Immunotherapeutic Production
Purpose of Review The requirement for large quantities of therapeutic proteins has fueled a great interest in the production of recombinant proteins in plant bioreactors. The vaccines and bio-therapeutic protein production in plants hold the promise of significantly lowering the cost of manufacturing life-saving drugs. This review will reflect the current status and challenges that the molecular farming platform faces becoming a strategic solution for the development of low-cost bio-therapeutics for developing countries. Recent Findings Different plant parts have been successfully identified as suitable expression systems for the commercial production of therapeutic proteins for some human and animal diseases ranging from common cold to AIDS. The processed therapeutics from such sources are devoid of any toxic components. The large-scale cultivation of these transgenic plants would be possible anywhere in the world including developing countries, which lack sophisticated drug manufacturing units. A couple of such commercially generated products have already hit the market with success. Newer methods using suitable plant viruses and recombinant gene expression systems have already been devised for producing therapeutic proteins and peptides. Summary Plants are promising bio-factories for therapeutic protein production because of their several advantages over the other expression systems especially the advanced mechanisms for protein synthesis and post-translational modification which are very much similar to animal cells. Plant biotechnologists are much attracted to the bio-farming because of its flexibility, scalability, low manufacturing cost, as well as the lack of risk of toxic or pathogenic contamination. A number of projects on bio-farming are designed and are at various developmental stages but have not yet become available to the pharmaceutical industry. Therefore, we need further advancement in the optimization of lab protocols for up-scaling the production of such therapeutics at commercial level with a promise to offer their best clinical use.
- 25 August 2016
- Published by Springer Nature
- Vol. 1469, 15-30
Method for Biolistic Site-Specific Integration in Plants Catalyzed by Bxb1 Integrase
Crop improvement is a never ending process. With a transgenesis approach, it is not inconceivable to envision a continuous addition of new transgenes to existing cultivars. Previously, we described a recombinase-directed gene stacking method in tobacco (Hou et al., Mol Plant 7:1756–1765, 2014). Being able to stack DNA to a previous location ensures that the number of genetic loci does not increase with each new round of transgene addition. Whereas the previous demonstration was conducted through polyethylene glycol to mediate uptake of DNA into tobacco protoplasts, we now describe protocols for using biolistic transformation to stack DNA in tobacco and rice.
- 25 August 2016
- Published by Springer Nature
- Vol. 1469, 15-30
Method for Biolistic Site-Specific Integration in Plants Catalyzed by Bxb1 Integrase
Crop improvement is a never ending process. With a transgenesis approach, it is not inconceivable to envision a continuous addition of new transgenes to existing cultivars. Previously, we described a recombinase-directed gene stacking method in tobacco (Hou et al., Mol Plant 7:1756–1765, 2014). Being able to stack DNA to a previous location ensures that the number of genetic loci does not increase with each new round of transgene addition. Whereas the previous demonstration was conducted through polyethylene glycol to mediate uptake of DNA into tobacco protoplasts, we now describe protocols for using biolistic transformation to stack DNA in tobacco and rice.